( heterocyclic)quinazolines, a Novel Class of Antimetabolites with

Department of Chemistry, Research and Development Division, Parke, Davis and Company, Hounslow, Middlesex, England. Received February 23, 19 72...
0 downloads 0 Views 1MB Size
Journal of Medicinal Chemistry, 1972, Vol. 1.5, No. 8

Folate Antagonists. 3

827

Folate Antagonists. 3. 2,4-Diamino-6-(heterocyclic)quinazolines,a Novel Class of Antimetabolites with Potent Antimalarial and Antibacterial Edward F. Elslager,* J. Clarke, Leslie M. Werbel, Donald F. Worth, Department of Chemistry, Research and Development Division, Parke, Davis and Company, Ann Arbor, Michigan 481 06

and John Davoll Department of Chemistry, Research and Development Division, Parke, Davis and Company, Hounslow, Middlesex, England. Received February 23, 19 72

Eleven 2,4-diamino-6-(heterocyclic)quinazolines(VI) were prepared by condensing 5-chloro-2-nitrobenzonitrile (111) with the appropriate saturated heterocycle to give the corresponding 5-(heterocyclic)-2nitrobenzonitriles (IV) (24-94%), followed by SnClz. 2Hz0 reduction to the 2-amino-S-(heterocyclic)benzonitriles (V) (5 1-85%) and cyclization to VI (6-7 1%) with chloroformamidine SHC1 or cyanoguanidine. The reaction of 2,4;6;triaminoquinazoline (33) with 2,5-diethoxytetrahydrofuran,acetonylacetone, phthalic anhydride, and c i , -dibromoxylene ~ afforded 2,4-diamino-6-(pyrrol- 1-y1)quinazoline (34), 2,4(35), N-( 2,4-diamino-6-quinazolinyl)phthalimide(36), diamino-6-( 2,5-dimethylpyrrol-1-yl)quinazoline and 2,4-diamino-6-( 2-isoindoliny1)quinazoline (37) in 26-8 5% yield. 2,4-Diamino-6-(3,5-dimethylpyrazol(39) by cyclization 1-y1)quinazoline (40) (63%) was prepared from 2,4-diamino-6-hydrazinoquinazoline with acetylacetone. Ring closure of 2,4,6,8-tetraaminoquinazoline(43) and 2,4-diaminod-(aminomethyl)quinazoline (46) utilizing acetonylacetone gave 2,4-diamino-6,8-bis( 2,5-dimethylpyrrol-l-yl)quinazoline (44) (53%) and 2,4-diamino-6-[(2,5-dimethylpyrrol-l-yl)methyll quinazoline (47) (69%), respectively. Thirteen heterocyclic quinazolines were active orally or parenterally against Plasmodium berghei in mice and P. gallinaceum in chicks. 2,4-Diamino-6-(2-phenyl-l-pyrrolidinyl)quinazoline (27) and 2,4-diamino-6(2-benzy1piperidino)quinazoline (3 1) showed activity comparable with or superior to cycloguanil hydrochloride and 2,4-diamino-6-[(3,4-dichlorobenzyl)nitrosamino]quinazoline(Ib). Many of the heterocyclic quinazolines were also highly active against a broad spectrum of pathogenic and nonpathogenic bacteria in vitro. 2,4-Diamino-6-(2,5-dimethylpyrrol1-yl)quinazoline (35) exhibited good activity against Streptococcus p y o g e n e s (C-203) in mice following single oral or sc doses ranging from 50 to 500 mg/kg, and the drug was synergistic with sulfamethoxypyridazine. In recent communications from these laboratories relating to folate antagonists,'-' it was reported that various 2,4-diamino-6- { [aralkyl and (heterocyclic)methyl] amino- and -nitrosamino)quinazolines, exemplified by 2,4-diamino-6[(3,4-dichlorobenzyl)amino]quinazoline (Ia)'y3 and 2,4-diI1

b;R=NO

amino-6- [(3,4-dichlorobenzyl)nitrosamino]quinazoline (Ib),46 exhibit strong antimalarial activity against sensitive and drugresistant lines of Plasmodium berghei in mice, P. gallinaceum in chicks, and P. cynomolgi and P. knowlesi in rhesus These substances also possess an encouraging degree of activity against Trypanosoma cruzi in chick embryo cell cultures and in m i ~ e ' 9 ~ 3and ~ 4 are potent folate antagonists in bacterial In contradistinction, various 2,4diamino- and 2-amino4hydroxyquinazoline Glu and Asp analogs7 (11, where x = 1 or 2; R = H or CH3; and X = OH or NH2) lack appreciable antiparasitic activity, but display potent inhibitory effects against Streptococcus faecalis R (ATCC 8043)' [Strep. faecium var. durans (SF/O)] ,9 thymidylate synthetase and dihydrofolic reductase from mammalian and bacterial sources,8 several tThis is paper 25 of a series on antimalarial drugs. For paper 24, see ref 1 . $This investigation was supported in part by U. S. Army Medical Research and Development Command Contract DA-49-193-MD2754. This is Contribution No. 922 to the Army Research Rogram on Malaria.

sublines of the L1210 mouse leukemia,'and L1210 cells in ~ u l t u r e . ~ We now report the synthesis and biological properties of various 2,4-diamino-6-(heterocyclic)quinazolines(VI), a novel series of antimetabolites with potent antimalarial and antibacterial activity. Chemistry. Many of the 2,4-diamino-6-(heterocyclic)quinazolines (VI) were prepared utilizing the route exemplified by Scheme I. The condensation of 5-chloro-2-nitroScheme I

CI I H,NC=NH, HCI NH /I or H,NCNHCN 6-7 1%

V

VI

benzonitrile (111) with the appropriate saturated heterocycle in 2-ethoxyethanol or DMSO afforded the corresponding 5-(heterocyclic)-2-nitrobenzonitriles(IV, 1-10, Table I) in 26-94%yield (procedures I, 11). Reduction of the nitro-

828

Elslager, et al.

Journal ofMedicina1 Chemistry, 1972, Vol. IS,No. 8

Table I. 5-(Heterocyclic)-2-nitrobenzonitriles

No.

l

2

MP, "C

Purificn solvent

Procedure

Formula

Analyses

127-128

94

EtOH

i

161-163

85

EtOH

1

180-1 82

76

MeCN

1

67

DMSO

11

Ci 7H13CLN3Oz

C, H,

189-192

90

MeCN

11

1'

C, H, N

188-191

77

DMSO

11

C17H15N302

162-164

39

EtOH

186-1 87

26

EtOH

1

C l , H l , N 3 0 ~ ~ 0 . 1 H z 0 C, H, N, HZO

H 3 C 6 H 5

220-222

86

DMF-H,O

1

C18Hl TN3'2

C, H,

o C H 2 C 6 H 5

120-126

47

EtOH

11

C19H19N302

C, H, N

n

N

NCH,

u

4

5

W

6

rkca5

7

Yield purified, %

W

C

C

I

l

3N302

CL2H14N402

C, H. N C, H,

N

C. H, N

,H1,C1N302

N

C, H, N

n

H3C 9

10

N

&.qNH2 &gqNHZ

Scheme I1

0

34

CH3 35 1

benzonitriles (IV) with SnCl2-2H2Oin aqueous HC1 or aqueous HCl-HOAc gave the 2-amino-5-(heterocyclic)benzonitriles (V, 11-20, Table 11) in 5 1-85% yield (procedures

36 0

111-V). Cyclization of the requisite aminobenzonitrile (V) with chloroformamidine hydrochloride'o in dry diglyme (procedure VI) or with cyanoguanidine in concd HC1 (pro-

Journal of Medicinal Chemistry, 1972, Vol. 15, No. 8

Folate A n tag0 nists. 3

829

Table 11. 2-Amino-5-(heterocyclic)benzonitriles

No.

Yield purified, %

Purificn solvent

Procedure

92-94

12

CC14-petr ether

111

CIZHIIN~

C, H, N

98-100

84

cc1,

IV

C12H16N4

C, H, N

117-120

58

EtOH-H,O

V

C14H19N3

C, H, N

128-130

85

CROH

V

C16H15N3

134-1 36

56

CROH

V

1‘

O

11

N

12

NuNCH,

13

MP, C 3

n N

a

Formula

Analyses

‘lH5

15

SaZN3

C, H, N

16

W C l

135-137

51

i-ROH

V

Ci~Hie.aN3

C, H, N

17

U C 6 H 5

217-221

68

EtOH-Et,O

V

CiWi,N,.HCl

C, H, Cl-,N

143-144

61

EtOH-H,O

V

CisHi9N3.0.06HiO

C, H, N, HZO

m 18

NJC6H5 H3C

19

N3C,H,

166-167

79

i-ROH

V

C18H19N3

C, H, N

20

oCH,C6H5

104-105

15

EtOH-H,O

V

C19H21N3

C, H, N

cedure VII) gave the desired 2,4-diamino-6-(heterocyclic)quinazolines [V,21-31,Table 111) (6-71%). Alternatively, various 2,4-diamino-6-(heterocyclic)quinazolines were synthesized from 2,4,6-triaminoquinazoline (33)7 via 2,4-diamino-6-nitroquinazoline (3217(Scheme 11). Thus the condensation of 33 with 2,5-diethoxytetrahydrofuran, acetonylacetone, phthalic anhydride, and cup’-dibromo-o-xylene afforded 2,4-diamino-6-(pyrrol- 1 -yl)quinazoline (34)(26, 30%), 2,4-diamino-6-(2,5-dimethylpyrrol1-y1)quinazoline (35) (40,48%), N-(2,4-diamino-6-quinazoliny1)phthalimide (36)(85%), and 2,4-diamino-6-(2-isoindoliny1)quinazoline (37)(75%), respectively. Diazotization of 33 gave the diazonium salt 38,which was reduced in situ with SnC12.2H20 to give 2,4-diamino-6-hydrazinoquinazoline (39)(42,54%). Cyclization of 39 with acetylacetone afforded 2,4-diamino-6-(3,Sdimethylpyrazol-l-yl)quinazoline (40)(26,63%). 2,4-Diamino-6,8-bis(2,5-dimethylpyrrol1-yl)quinazoline (44)was readily synthesized starting from 3,S-dinitro-oanisonitrile (41)” (Scheme 111). Ring closure of 41 with guanidine hydrochloride gave 2,4-dimino-6,8-dinitroquinazoline (42)in high yield (85,86%). Hydrogenation of 42 over 10% Pd/C afforded 2,4,6,8-tetraahinoquinazoline(43) (93,96%), which was condensed with 2 equiv of acetonylacetone to give 2,4-diaminod,8-bis(2,5-dimethylpyrrol1 -yl> quinazoline (44)(30, 53%). 2,4-Diamino-6- [(2,5-dimethylpyrrol-l-yl)methyl] quinazoline (47),the methylene homolog of 35,was also prepared starting from 2,4,6-triaminoquinazoline(33)7 (Scheme IV).

Scheme 111

NH, 42

41 NH,

43 H,C

J n N

CH,

@TN% &H

NH, CH,

44

The triamine was first converted via the Sandmeyer reaction to the known 2,4diamino-6quinazolinecarbonitrile (45),7 which was hydrogenated over Raney Ni at 70-75’ (1 00 atm) to give 2,4-diamino-6-(aminomethyl)quinazoline(46)in 5382% yield. Cyclization of 46 with acetonylacetone afforded the desired product (47)in 60459% yield. Spectral data (ir, uv, nmr) were in agreement with the structures shown for each of the 2,4-diaminod-(heterocyclic)quinazolines.

830

Elslager, et al.

Journal of Medicinal Chemistry, 1972, Vol. 15, No. 8

Table 111. 2,4-Diamino-6-(heterocyclic)quinazolinesvia 5-Chloro-2-nitrobenzonitrile

No.

MP, "C

21

n

N

22

NCH,

u

N3

23

Yield purified, %

292-294

40

286-292

71

320-323

29

Na

Purificn solvent

EtOH-H,O

EtOH-H,O

Procedure

VI

Formula

Analyses

7N 5

C, H, N

VI

Ci3HisN6

C, H, N

VI

C, ,H,,N,. HC1. 0.05H20

C, H, Cl-, N,

1

'ZH5

h20

248-25 1

34

MeOH

v11

C,7H,7N5~2C7H803SaC, H, N, S

25

149-152

31

i-&OH-MeCN

VI

cl IH1 7C12N5

C, H, N

26

145-147

45

i-Pr OH-MeCN

VI

27

246-241

26

EtOH

v11

28

200-205 dec

21

i-PrOH-MeCN

VI

C19H20C1N5

H, N; Cb

44

DMF

VI

C1,H,,N5~HC1

C, H, Cl-. N

28

MeOH

v11

C19H21N5

C, H, N

6

EtOH

VI

C2,H,,N5~0.25H,0

C, H, N,H,O

24

>300

29

30

255-257 dec

31

108-112

'T7H,0,S represents p-toluenesulfonic acid. k : calcd, 64.5; found, 63.9. Scheme IV

33

45

Ni, H, 5 3 , 8 0 , 82%.

W N H (CH&OCH,),, 2

60,69%

H,NCH, NH, 46

47

The pyrrolidine, piperidine, and piperazine intermediates required for the synthesis of compound 21-24,30, and 31 are commercially available. 2-(3,4-Dichlorophenyl)pyrrolidine, 2-@-chlorophenyl)pyrrolidine, l2 and 2-phenylpyrrolidine13 were obtained by the reaction of the requisite phenylmagnesium bromide and 4-chlorobutyronitrile to give the corresponding 2-phenyl-l-pyrroline~,'~ which were hydrogenated over 5% Pt/C. 2-@-Chloropheny1)piperidine was pre-

pared by the condensation of p-chlorophenylmagnesium bromide with 5-chlorovaleronitrile to give 2-@-chlorophenyl)3,4,5,6-tetrah~dropyridine,'~ followed by hydrogenation in HOAc over Pt/C. Attempts to reduce 2-methyl-3-phenyl-Ipyrroline to 2-methyl-3-phenylpyrrolidine with NaBH4 were unsuccessful, but catalytic hydrogeqation utilizing Pt/C afforded the intermediate 2-methyl-3-phenylpyrrolidjne. Antimalarial Effects. Antimalarial studies with the 2,4diamino-6-(heterocyclic)quinazolinesdescribed in the present communication were carried out utilizing P.berghei in mice and P. gallinaceum in chicks. Compounds 23,25,26,28,29, and 31 were administered sc in a single dose to mice infected withP. bergheis,#(Table IV). Five substances (23; 25,26, 28,31) cured all of the mice at one or more dose levels ranging from 40 to 640 mg/kg, but four of them, like cycloguanil hydrochloride, were toxic for mice at the higher dose levels. 2,4-Diamin0-6-(2-benzylpiperidino)quinazoline(3 l), the most promising member of the series, exhibited activity comparable with or superior to cycloguanil hydrochloride, 2,4-diamino-6- [(3,4-dichlorobenzyl)amino] quinazoline (Ia), and 2 ,Cdiaminod- [(3,4-dichlorobenzyl)nitrosamino]quinazoline (Ib). $The parenteral antimalarial screening was carried out by Dr. Leo Rane of the University of Miami, and test results were provided through the courtesy of Dr. David P. Jacobus, Dr. T. R . Sweeney, and Dr. E. A. Steck of the Walter Reed Army Institute of Research. #For a description of the test method, see ref 1 5 .

Journal of Medicinal Chemistry, 1972, Vol. 15, No. 8

Folate Antagonists. 3

831

Table IV. Parenteral Effects of 2,4-Diamino-6-(heterocyclic)quinazolines against Plasmodium berghei in Mice

AMST; T or C? after single mg/kg dose

NO.^

640

23

T5

25

T5

26

C2, T3

28

29 31

1.9 c5

320

160

80

40

20

10

c5 c5 C2, T3 C2, T3 C2, T3 C2, T3 T5

c5 c5 C2, T3 C2, T3 C4, T1 C4, T1 C2, T3 C1, T4 0.5 c5 c5

13.7; C1 13.4; C1 c5 c5 c5 c5 c5 c5 0.3 c5 c5

8.9 8.7 9.9; c 4 20.4; C3 20.9; C3 17.9; C4 c5 c5 0.3 c5 c5 c5 13.4; C1 13.4; C1 7.1 7.3

3.3 3.1 7.5 7.7 18.2; C2 21.1; c1 1.5 7.3 0.3 9.9; c 3 11.4; C3 12.4; C3 7.9 8.1 2.5 2.1 22.4; C1

0.7

0.5 c5 c5

2.5 7.7 4.3b 4.5 6.7c 6.9

4.9 C3, T2 21.6; C2 c5 C2, T3 21.9; C2 c5 12.9 0.7 Ia acetate c5 c5 9.9; c 3 13.1 0.7 c5 9.9; c 3 Ib acetate c5 c5 =AMST is themean survival time (days) of treated mice (MSTT) minus the mean survival time (days) of control mice (MSTC). In the present study the MSTC was 6.1 days. T signifies the number of toxic deaths, occurring on days 2-5 after infection, which are attributed to drug action. C indicated the number of mice surviving at 60 days post infection and termed "cured"; data to establish parasitological cure based on subinoculation are unavailable. Each compound was administered as a single sc dose. Each entry at each dose level represents results with a 5 animal group. bAMST at 5 mg/kg = 2.7 days; CAMST = 5.1 days at 5 mg/kg, 1.7 days at 2.5 mg/kg, and 0.5 days at 1.25 mg/kg. dStructures for het N are given in Table III. Cycloguanil hydrochloride

T5

Twelve compounds (21,22,24,27,30,34-37,40,44,47) were given by gavage for 4 days or continuously b y drug-diet for 6 days to mice infected with another normal drug-sensitive strain of P. berghei**ytt (Table V). Among them, seven quinazolines (21,24,27,30,34,44,47) produced a 90% suppression of the parasitemia at daily oral doses ranging from 0.35 to 16 mg/kg. 2,4-Diamino-6-(2-phenyl1-pyrrolidiny1)quinazoline (27),the outstanding member of the group, was approximately 210 times as potent as quinine hydrochloride and compared favorably with 2,4-diamino- [6(3,4-dichlorobenzyl)nitrosamino]quinazoline (Ib).*y6 Several of the heterocyclic quinazoline derivs (23,25,26) were also evaluated against P. gallinaceum infections in w h t e Leghorn cockerels.$$ Chicks were given an iv injection of 0.2 ml of heparinized blood infected with P. gallinaceum and having a minimum of 80-90% parasitized red blood cells. The parasitized blood was drawn by cardiac puncture from donor birds infected 72 hr earlier with P. gallinaceum. Donor strains were maintained in separate groups of chicks, 14-16 days old, that also received inoculations of heparinized infected blood. In every experiment 100% of the untreated control birds died within 72-96 hr postinfection. Candidate substances were administered to chicks in a single sc dose in peanut oil immediately after infection. In this test, as in the mouse test, the antimalarial activity of candidate compounds was assessed by comparing the maximum survival times of treated malaria-infected chicks with the survival times of untreated malaria-infected controls. A compd was arbitrarily **Selected compounds were kindly studied orally against P. berghei in mice by Dr. Paul E. Thompson and coworkers, Department of Pharmacology, Parke, Davis and Co., Ann Arbor, Mich. ??For a description of the test method, see ref 3 and 4. $$Antimalarial screening against Plasmodium gallinaceum in chicks was carried out by Dr. Leo Rane at the University of Miami, and test results were supplied through the courtesy of Dr. David P. Jacobus, Dr.T. R. Sweeney, and Dr.E. A. Steck of the Walter Reed ~

Army Institute of Research.

considered to be active against malaria if it produced increases in the survival times of treated chicks that were at least 100% over the survival times of untreated controls. As indicated in Table VI, all these substances were active based on these criteria and each prolonged the survival time of chicks for periods of 3.8-16.0 days following a single sc or iv dose ranging from 7.5 to 160 mg/kg. However, none was as promising as cycloguanil hydrochloride or the two diaminoquinazoline reference drugs (Table VI). Antibacterial Studies. Each of the 2,4-diamino-6-(heterocyc1ic)quinazolines was tested in vitro against a spectrum of pathogenic bacteria including Streptococcus faecalis (MGH-2), normal (UC-76) and drugresistant (S187 13) Staphylococcus aureus, Pseudomonas aeruginosa (28), Escherichia coli (Vogel), and Shigella sonnei ((2-10). A modification of the gradient plate procedure of Szybalski16 and Webb and Washington" was employed throughout. Fourteen compounds were active against Strep. faecalis (MGH-2) at